Conversely, suppression of PPARγ signaling by its antagonist may inhibit adipocyte differentiation, reduce body weight, and improve metabolic disorders in C57BL/6 mice [16, 17], suggesting that PPARγ is a potential target for obesity therapy. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.